Drugs / HM201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05088369 | Nov 2021 → Dec 2022 | Crohn disease, ulcerative colitis | Syneos Health | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-04-07 | Himuka AM Pharma Corp. | Results オーストラリアでのHM201の第Ⅰ相臨床試験が終了しました。 himuka-am.com ↗
The preliminary results of this study demonstrated excellent data with final results scheduled to be reported in several months. |
| 2021-11-04 | Himuka AM Pharma Corp. | Regulatory HM201の第Ⅰ相臨床試験計画承認を受けました。 himuka-am.com ↗
Himuka AM Australia Pty Ltd. today announced the approval by the Human Resources Ethical Committee of Himuka’s application for a Phase 1 Clinical Trial of HM201 in Australia. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-07 | Himuka AM Pharma Corp. | オーストラリアでのHM201の第Ⅰ相臨床試験が終了しました。 himuka-am.com ↗ |
| 2021-11-04 | Himuka AM Pharma Corp. | HM201の第Ⅰ相臨床試験計画承認を受けました。 himuka-am.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05088369 ↗ |
| Route | Intravenous | “HM201 will be administered intravenously.” NCT05088369 ↗ |